In 2015, the agency said the vaccine was safe (with some issues it wanted GSK to continue to study), and PATH began hunting for new financial partners to replace Gates.
If this small-chance issue turned out to be an actual problem, it could undermine African parents’ confidence in all childhood vaccines, with catastrophic consequences.
Gavi turned to MedAccess, an organization that provides funding to reduce the financial risk for private companies working on medical products for low-income nations.
and other agencies suggested it was because the company was keeping most of the adjuvant for more lucrative products such as its shingles vaccine, Shingrix, which sells for $350 per dose (compared with $10 for the malaria shot).
pilot study was worth the years it added — was it better to err on the side of caution, because the stakes were so high for children’s health, or to gamble, given the scale of malaria’s devastation?
Some of the lessons from the malaria experience have been applied to the tuberculosis vaccine, but it is made with the same GSK adjuvant and key questions about supply remain unresolved.
The original article contains 2,026 words, the summary contains 184 words. Saved 91%. I’m a bot and I’m open source!
This is the best summary I could come up with:
In 2015, the agency said the vaccine was safe (with some issues it wanted GSK to continue to study), and PATH began hunting for new financial partners to replace Gates.
If this small-chance issue turned out to be an actual problem, it could undermine African parents’ confidence in all childhood vaccines, with catastrophic consequences.
Gavi turned to MedAccess, an organization that provides funding to reduce the financial risk for private companies working on medical products for low-income nations.
and other agencies suggested it was because the company was keeping most of the adjuvant for more lucrative products such as its shingles vaccine, Shingrix, which sells for $350 per dose (compared with $10 for the malaria shot).
pilot study was worth the years it added — was it better to err on the side of caution, because the stakes were so high for children’s health, or to gamble, given the scale of malaria’s devastation?
Some of the lessons from the malaria experience have been applied to the tuberculosis vaccine, but it is made with the same GSK adjuvant and key questions about supply remain unresolved.
The original article contains 2,026 words, the summary contains 184 words. Saved 91%. I’m a bot and I’m open source!